Bellerophon Therapeutics Shares Gained Over 200% Today
Bellerophon Therapeutics Inc (NASDAQ:BLPH) entered into a license agreement for the development and commercialization of INOpulse with Baylor BioSciences.…
INVO Bioscience Enters 1-Year Distribution Agreement For Taiwan
INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device
Bellerophon Therapeutics Announces License Agreement For The Commercialization Of INOpulse In Greater China With Baylor BioSciences
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today
CPI Aero Receives $1.8M Follow-On Order For Welded Fluid Tank Assemblies
CPI Aerostructures, Inc. (CPI Aero® or the Company) (NYSE:CVU) announced today that an undisclosed aerospace OEM has awarded CPI Aero a $1.8 million contract for complex welded fluid tank assemblies for an
Parsons’ BlackHorse Solutions Subsidiary Receives $12M Contract From DARPA
CENTREVILLE, Va., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE:PSN) announced today that the company's BlackHorse Solutions subsidiary won a $12 million contract from the Defense Advanced
Equinor, RWE Partner On Hydrogen Supply Chain To Help Germany Ease Out Coal Dependency
Equinor ASA (NYSE:EQNR) has partnered with the German energy company RWE AG (OTC:RWEOY) to jointly develop large-scale value chains for low carbon hydrogen.…
University Hospitals In Cleveland Enters Into Master Purchase Agreement With ViewRay For Multiple MRIdian Systems
ViewRay, Inc. (NASDAQ:VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase
Reported Late Wednesday, FP Credit Partners II, L.P. And FP Credit Partners Phoenix II, L.P. Announce Termination Of Pathfinder Acquisition Corporation Tender Offer To Purchase Up To An Aggregate Of $75M Of Class A Ordinary Shares
FP Credit Partners II, L.P. ("FPCP") and FP Credit Partners Phoenix II, L.P. ("FPCPP" and together with FPCP, the "Purchasers") today announced that they have terminated their previously
Reported Late Wednesday, WuXi Biologics And GSK Enter Into License Agreement On Multiple Novel Bi- & Multi-specific T Cell Engagers; Wuxi Biologics Will Receive An Upfront Payment Of $40M And Tiered Royalties On Net Sales
WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi
Reported Late Wednesday, IntoCell Enters Into Development And License Option Agreement With ADC Therapeutics
IntoCell today announced the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA (NYSE:ADCT).
Under the agreement, IntoCell, a South Korean biotech developing novel antibody